RELATED CONTENT
NEWS
- Australian panel recommends transparency overhaul at TGA
- Comparative efficacy should have a "formal role in drug licensing"
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
- NICE revises earlier green light for Roche's MabThera as maintenance treatment
COMMENT
FEATURES
Other Informa Features


